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Objective: To evaluate left ventricular (LV) systolic function by means of echocardiography in patients with osteosarcoma 
treated with doxorubicin alone or in combination with dexrazoxane.
Methods: The study analyzed 55 patients with osteosarcoma, with or without metastasis, undergoing a six-cycle chemothera-
py regimen of doxorubicin, who were divided into two groups according to dexrazoxane use. Group I: Thirty-seven patients 
who did not receive dexrazoxane (28 males, average age 15.4 years). Group II: Eighteen patients who did receive dexrazo-
xane (15 males, average age 15.1 years). Four echocardiographic evaluations were performed: 1) before the beginning of the 
chemotherapy (initial evaluation); 2) up to two weeks after the third cycle; 3) up to two weeks after the fifth cycle; and 4) up 
to four weeks after the sixth cycle of chemotherapy (final evaluation). The left ventricular systolic function was assessed by the 
fractional percentage of systolic shortening (FS%) on echocardiography. Alterations in the contractile function or cardiac toxi-
city were defined as FS% values equal to or lower than 29%, and/or by a drop in FS% by an absolute value equal to or greater 
than 10 units of the baseline value of each patient.
Results: No significant difference as to age, gender, and race was observed between the groups. The cumulative dose of do-
xorubicin was significantly higher in group II throughout all phases of the treatment: 174 x 203 mg/m2; 292 x 338 mg/m2 and 
345 x 405 mg/2 (p < 0.0001). According to previously established criteria, the incidence of LV systolic dysfunction was not 
significantly different (p=0.248) between patients in group I (18.92%) and patients in group II (11.1%). The variance analysis 
with repeated measurements did not show significant differences in the means of fractional percentage of systolic percentage 
(FS%) throughout the study (p=0.967). However, a significant difference (p=0.029) was observed between the FS% means in 
groups I and II at evaluations 2 (35.67 x 37.21%), 3 (34.95 x 38.47%) and 4 (35.26 x 38.22%).
Conclusion: Data in this study show that in patients with osteosarcoma treated with doxorubicin alone or combined with 
dexrazoxane, the LV systolic function, as assessed by the fractional percentage of systolic shortening mean, showed a better 
performance in the group that received dexrazoxane. On the other hand, the occurrence of systolic dysfunction was similar 
in both groups.
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Currently, children with neoplasms have increasingly higher 
chances of being cured of their diseases. The introduction of 
anthracyclines in chemotherapy regimens for the treatment 
of malignant neoplasms is one of the greatest advances in 
modern oncology. According to data from North-American 
investigators, more than 50% of children treated with this class 
of cytostatic agent were cured between 1974 and 19901. Its 
broad spectrum of antitumoral activity especially encompasses 
the treatment of hematological neoplasms such as lymphomas 
and leukemia, and solid tumors including breast, ovarian, and 
thyroid cancer, soft tissue sarcoma, and osteosarcoma2.
The use of new antiemetic drugs (serotonin receptor 
inhibitors) and granulocyte colony-stimulating factors reduced 
the clinical significance of adverse effects such as nausea, 
vomiting and neutropenia. This allowed increases in the doses 
of anthracyclines3. On the other hand, the cardiotoxicity 
induced by this drug has not yet been entirely overcome, and 
it remains a major impediment to administering higher doses 
that could enhance its therapeutic potential. Therefore, this 
is an issue that remains unsolved, despite the fact that the 
first reports on cardiac toxicity were published approximately 
three decades ago4.
Billingham et al5 were the first to systematically describe the 
histological and ultrastructural alterations in anthracycline-
induced cardiac lesions. These authors described two distinct 
types of lesion in the myocyte: (1) myofibrillar loss, and (2) 
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production of the iron-doxorubicin compound involved in 
the formation of the free radicals that cause cardiac injury19. 
Several studies have shown the efficacy of dexrazoxane 
in protecting the myocardium against the toxicity caused 
by doxorubicin in adults and children20-22. However, there 
are few studies on the use of dexrazoxane in children with 
osteosarcoma in medical literature, none in Brazil. Thus, the 
objective of this study was to analyze the behavior of the left 
ventricular systolic function by means of echocardiography in 
patients with osteosarcoma treated with doxorubicin alone or 
in combination with dexrazoxane.
Methods
Patients - Fifty-five patients were followed up at the Instituto 
de Oncologia Pediátrica (Institute of Pediatric Oncology) and 
at the Setor de Cardiologia Pediátrica da Universidade Federal 
de São Paulo – Escola Paulista de Medicina - UNIFESP – EPM 
(Department of Pediatric Oncology of the Federal University 
of São Paulo), from May 1996 to February 2001. This study 
was approved by the Institutional Research Ethics Committee 
of UNIFESP – EPM. An informed consent form was signed by 
the patients’ families or, whenever possible, by the patient 
himself/herself, after the necessary explanations were given. 
Inclusion criteria were the same as those for the Protocol IV 
(1996) of the Grupo Brasileiro de Tratamento de Osteossarcoma 
– GBTO (Brazilian Group of Osteosarcoma Treatment 
– GBTO), as follows: (1) patients recently diagnosed with highly 
malignant osteosarcoma not induced by irradiation, confirmed 
by biopsy and not previously treated; (2) patients with 
osteosarcoma at any primary site with or without metastases; 
(3) patients under the age of 21; (4) patients with no evidence 
of cardiovascular disease, current or previous, based on clinical 
history, physical examination, electrocardiogram, chest X-ray 
and echocardiogram; (5) patients with normal kidney and 
liver functions.
This is a prospective non-randomized study with two 
sequential groups formed according to dexrazoxane use. Group 
I consisted of patients who did not receive dexrazoxane as the 
drug was not yet available in our context, and Group II was 
subsequently formed by patients who received dexrazoxane 
when this agent became available at our institution. Group I 
consisted of 37 patients, 28 males and 9 females, average age 
15.4 years. Group II consisted of 18 patients, 15 males and 3 
females, average age 15.1 years.
Patients were treated according to Protocol IV (1996) of 
the Grupo Brasileiro de Tratamento de Osteossarcoma – GBTO 
(Brazilian Group of Osteosarcoma Treatment – GBTO). The 
chemotherapy regimen included the following drugs: cisplatin, 
carboplatin, doxorubicin and ifosfamide. In order to reduce 
kidney toxicity induced by ifosfamide, the renoprotective 
agent Mesna was used. Doxorubicin was intravenously 
administered in six cycles, three in the preoperative phase 
and three in the postoperative phase, in doses of 60 mg/m2 
for group I and 70 mg/m2 for group II (in rapid infusions of 
30 minutes each). Dexrazoxane was used at a rate of 20:1 
relative to the dose of doxorubicin, milligram to milligram, and 
administered intravenously in rapid 15-minute infusions begun 
approximately 30 minutes before the doxorubicin infusion.
vacuolar degeneration. At a more advanced stage, both types 
of lesion progressed to mitochondrial degeneration followed 
by the formation of myelin figures and nuclear disintegration, 
culminating with myocyte death and resulting myocardial 
fibrosis. It has been proven that several mechanisms are 
involved in the pathogenesis of the myocardial injury induced 
by anthracyclines, which are independent of their antitumoral 
activity. However, most studies associate cardiotoxic effects to 
the formation of reactive oxygen types (free radicals) such as 
the superoxide anion (O2-) and the hydroxyl radical (OH-). 
These are responsible for the lipid peroxidation of several 
cellular sites including cell membranes, nuclear membranes, 
and the membranes of several cytoplasmatic organelles, 
mainly mitochondria and the cytoplasmatic reticulum, 
leading to a chain of autocatalytic reactions responsible for 
the destruction of the myocyte6-9.
The anthracycline-induced injury to the myocardium 
depends on an ample individual variability and on a set of risk 
factors that contribute to increase the injury, such as the total 
cumulative dose of doxorubicin, administration form (rapid 
or slow infusion), combination with other cytostatic agents, 
previous or concomitant irradiation of the mediastinum, and 
patients under 15 years or over 65 years of age10-14. Of these, 
the cumulative dose of anthracycline is considered the main 
risk factor involved in the development of anthracycline-
induced myocardic toxicity10,12,15. 
Cardiac toxicity induced by doxorubicin or similar drugs 
may manifest itself during any stage of the chemotherapy, 
or even months or years after the end of the treatment. 
Four different forms of cardiac toxicity are described. Acute 
toxicity takes place immediately or a few days after the 
infusion of doxorubicin and is characterized by nonspecific 
electrocardiographic findings, typically transient changes 
in T wave and ST segment, conduction disorders, and 
sinus tachycardia16,17. Subacute toxicity usually occurs a 
few days or weeks after the last dose of the drug, and its 
main manifestation is toxic pericarditis and/or myocarditis 
(myopericarditis syndrome), which is usually reduced upon 
discontinuation of anthracyclin3,18. Chronic toxicity may have 
an early onset during the first year following the end of the 
chemotherapy, or a late onset, when it occurs after this period. 
Both types of toxicity manifest themselves under the form of 
a diffuse myocardiopathy, with clinical symptoms similar to 
those of other dilated myocardiopathies3,13,19.
Several strategies have been employed to avoid or minimize 
the cardiac injury caused by doxorubicin: administration of 
cumulative doses at levels considered more secure, slow 
infusion of the drug (6 to 72 hours), periodical monitoring of 
the cardiac function by supplementary tests (echocardiogram, 
radionuclide angiography, endomyocardial biopsy etc) and 
the use of drugs that may act as protective agents of the 
myocardium (dexrazoxane, probucol etc)11,12,20,25,36.
Dexrazoxane is widely recognized as a protective agent 
against anthracycline-induced cardiac toxicity. It is currently 
the only drug authorized for this indication in the United 
States. Since it is a hydrosoluble nonpolar substance, 
dexrazoxane easily reaches the cytoplasm of the cardiac cell 
where it is hydrolyzed in the shape of open rings, acquiring 
a strong iron-chelating property by which it prevents the 
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Echocardiogram - Was performed by one single operator, 
blinded to dose of anthracycline given to the patients and to 
which patients were receiving dexrazoxane. The equipment 
used were Ultramak 9 (ATL – Advanced Technology 
Laboratories, Bothel, WA-USA) and Philips SD 800 (Irvine, 
CA, USA), with 2.50 and 5.0 MHz transducers, capable 
of obtaining uni- and bidimensional images, as well as an 
analysis of the flow rate by Doppler spectral techniques and 
color flow mapping. Four echocardiographic evaluations were 
performed: 1) up to two weeks before the beginning of the 
chemotherapy (initial evaluation); 2) up to two weeks after 
the third cycle of doxorubicin; 3) up to two weeks after the 
fifth cycle of doxorubicin; and 4) up to four weeks after the 
administration of the last dose of doxorubicin (final evaluation). 
Patients were positioned in the left lateral decumbent position. 
Echocardiogram images were obtained in the conventional 
planes and recorded on video-tape (VHS) for posterior 
analysis. A complete echocardiographic examination was 
performed. Measurements of the diastolic diameter (Dd) 
and systolic diameter (Sd) of the left ventricule (LV) by M 
or bidimensional mode were utilized for the analysis. Dd 
was obtained at the point of maximum diastolic posterior 
deflection of the posterior LV wall, and the Sd at the point of 
maximum anterior deflection of the same wall, according to 
American Society of Echocardiography recommendations15. 
The parameter used to evaluate the left ventricular systolic 
function was the fractional percentage of systolic shortening 
(FS%) that corresponds to the percentage of reduction of the 
left ventricular diastolic diameter after its contraction and that 
can be calculated as (DdLV-SdLV)/(DdLV) x 100 (%). Values 
equal to or higher than 30% are considered normal. Left 
ventricular systolic dysfunction was defined according to the 
report of the Committee of Cardiology of the Group of Studies 
of Children with Cancer in the United States as FS% equal to 
or less than 29%, and/or a drop in FS% by an absolute value 
equal to or greater than 10 units of the value recorded before 
the beginning of chemotherapy of each patient22,24.
Laboratory exams - Heart rate and systolic and diastolic 
blood pressure for each patient were recorded during the 
echocardiogram, as well as the most recent blood hemoglobin 
and creatinine values.
Statistical analysis - The descriptive analysis of age was 
expressed as mean and standard deviation, whereas the 
cumulative dose and the shortening percentage were 
expressed as mean and standard error. Variance analysis with 
repeated measurements was used to evaluate the cumulative 
dose, clinical characteristics, diameters of the left ventricular 
cavity, and the shortening percentage. Gender, race and the 
incidence of ventricular dysfunction were evaluated with 
Fisher’s exact test. Age, weight, height and body surface area 
were calculated with the t Student test. For all tests performed, 
a p<0.05 descriptive level was considered as significant.
Results
In Group I, 140 echocardiographic exams were performed 
and eight were not performed, five because the patients 
missed the exam, and three due to deaths not related to 
cardiac toxicity. In Group II, 59 echocardiographic exams 
were performed; thirteen were not performed because the 
patients missed the exam, and three due to deaths not related 
to cardiac toxicity.
No significant difference was observed between the groups 
as to gender (Fisher’s exact test: p = 0.731), race ( Fisher’s 
exact test: p = 0.334), age (t Student test: p = 0.86), weight 
(t Student test: p = 0.719), height (t Student test: p = 0.563), 
BSA (t Student test: p = 0.563), and presence of metastases at 
the beginning of the treatment (Fisher’s exact text: p = 1.000) 
as Tables 1, 2, 3 and 4 show. Likewise, there was no statistically 
significant difference between groups I and II throughout the 
study as to heart rate (p = 0.554), systolic blood pressure (p 
= 0.95) and diastolic blood pressure (p = 0.465) as shown 
on Table 5. Both groups had hemoglobin level means greater 
than 8.0 g/dl, and serum creatinine levels lower than 1.0 
µmol/l during the echocardiographic evaluations, as shown 
on Table 6.
The cumulative dose mean was approximately 15% greater 
in Group II, as compared to Group I, in evaluations two, three 
and four. The statistical analysis shows that Group I presented 
values significantly greater of cumulative doses of doxorubicin 
(repeated measurement variance analysis: p < 0.0001) in 
evaluations 2, 3 and 4 as shown in Figure 1 and Table 7.
Table 8 shows the descriptive analysis of means and standard 
deviations of the left ventricle FS% on echocardiogram during 
the four evaluations. The left ventricular FS% behavior 
throughout the follow-up was evaluated as per the repeated 
measurements variance analysis. The conclusion of this 
statistical analysis was that there is interaction between group 
and evaluation (p = 0.356), which indicates that the behavior 
of both groups was similar throughout the study. Moreover, 
there is no significant difference (p = 0.967) between the 
means of shortening fraction percentage during the study 
in each group. On the other hand, there is a significant 
difference (p = 0.029) between the means of shortening 
fraction percentage in both groups in evaluations 2, 3 and 4, 
gender
Male Female Total
Group I 28 9 37
Group II 15 3 18
Total 43 12 55
Table 1 - distribution of patients in groups I and II as to gender.
Race
White Black Other Total
Group I 25 7 5 37
Group II 14 4 0 18
Total 39 11 5 55
Table 2 – distribution of patients in groups I and II as to race.
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as shown in Figure 2.
According to criteria previously defined and taking into 
account all evaluations, seven patients had left ventricular 
systolic dysfunction in group I (18.92%), and two patients in 
group II (11.1%). The statistical analysis showed that there was 
no statistically significant difference between the two groups, 
as shown on Table 9. In group I, out of the seven patients 
who had systolic dysfunction, five progressed towards normal 
levels before the end of the chemotherapy. In group II, the 
two patients who had systolic dysfunction progressed towards 
normal levels even before the end of the chemotherapy.
Discussion
Virtually all patients undergoing chemotherapy, or those 
who had been previously treated with doxorubicin, may 
develop cardiac toxicity induced by this chemotherapic agent. 
For this reason, with the development of each new protocol 
for the treatment of neoplasms, a few measures are taken to 
prevent, or at least reduce, this effect. 
Concerning the prevention of doxorubicin-induced cardiac 
toxicity, this study had a few important aspects such as: (1) 
the total dose of doxorubicin was divided into six cycles, 
with average intervals of three weeks; (2) in each cycle, the 
dose of doxorubicin was divided in half and given on two 
consecutive days, which reduces even more the peak of the 
drug’s serum level without compromising the area under the 
curve of plasma concentration; (3) cumulative dose limit of 
doxorubicin between 360 and 420mg/m2; (4) administration 
of dexrazoxane to one of the groups; and (5) the serial 
echocardiograhic evaluation in order to identify early cardiac 
changes and individualize the doxorubicin dose, if necessary. 
On the other hand, the administration of doxorubicin in rapid 
30-minute infusions is opposed to the trend in many oncology 
centers that prefer to administer doxorubicin in prolonged 
infusions (6 to 72 hours), claiming that this approach would 
produce a smaller cardiac toxicity risk25-29. However, despite 
the soundness of this argument, there are some negative 
aspects related to prolonged infusions of doxorubicin that 
keep it from being unanimously accepted. One of them is 
the significant increase of mucositis30,31. Another negative 
aspect is the possibility of tumor cells becoming resistant32. 
Moreover, it increases the duration of hospital stays, requires 
an infusion pump and central venous access catheter, making 
this approach uncomfortable for the patient and increasing the 
risk of bacteremia. In short, these factors increase the cost of 
the treatment, which is an important aspect to be considered 
in our environment. 
In the United States, the recommended dosage of 
dexrazoxane is 10 times that of doxorubicin (10:1), i.e., for 
each 1 mg/m2 of doxorubicin, 10mg/m2 of dexrazoxane are 
used19. Also, dexrazoxane is administered from the moment 
the patient reaches a cumulative dose of doxorubicin equal to 
or greater than 300mg/m2. In this study, dexrazoxane was used 
only for patients in group II, in an amount 20 times that of the 
doxorubicin (20:1) from the first dose of the chemotherapic 
agent, according to the recommendation made in Europe33.
There was no significant difference between the two 
groups as to predisposing factors or risk factors to develop 
doxorubicin-induced myocardial toxicity such as age, 
gender, and race, indicating that both drugs are comparable 
in these aspects. Moreover, as none of the patients received 
radiotherapy of the mediastinum, this form of treatment 
was not considered a risk factor for cardiac toxicity. The 
evaluation of laboratory data over the chemotherapy period 
showed that the levels of hemoglobin and creatinine were not 
interfering factors regarding the parameters evaluated, since 
they remained within acceptable levels (above 7.0 g/dl) in the 
two groups studied.
Among the other drugs used for the treatment of the 
patients in this study, beside doxorubicin only ifosfamide 
may cause toxicity34,35. Although the cardiac toxicity caused 
by ifosfamide may be potentialized by the association with 
doxorubicin13, both groups received similar doses of this 
medication and, therefore, it is impossible to infere that 
the association of these drugs resulted in an increased 
myocardial toxicity. 
Age (years) weight (kg) height (cm) bSA (m2)
Group I
Mean 15.4 46.96 155.76 1.38
Standard deviation 4.18 15.92 17.57 0.31
Group II
Mean 15.1 48.64 158.48 1.47
Standard deviation 4.57 16.4 14.85 0.29
t Student test p = 0.86 p = 0.719 p = 0.563 p = 0.563
Table 3 – Means and standard deviation of age, weight, height and body surface area (bSA) in groups I and II at the beginning of the study.
group I gorup II
Metastasis n % n %
Yes 8 21.6 3 16.7
No 29 78.4 15 83.3
Total 37 100 18 100
n- number of individuals.
Table 4 – Incidence of metastasis in groups I and II at the 
beginning of the study.
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In this study, the occurrence of left ventricular systolic 
dysfunction according to criteria previously defined showed no 
statistically significant difference (p=0.248) in group I (18.92%) 
and in group II (11.1%). Moreover, none of the two groups 
presented significant changes in the mean values of shortening 
fraction throughout the study, in all evaluations. Based on 
this information, it is possible to deduct that dexrazoxane 
did not have a clear influence as to myocardial protection. 
Nonetheless, there is an important consideration to be made. 
The mean shortening fraction was greater in group II than in 
group I, in evaluations number two, three and four, suggesting 
some level of myocardial protection granted by dexrazoxane. 
This hypothesis is corroborated by the fact that doxorubicin-
induced cardiac toxicity is dose-dependent, and in each one 
of these evaluations, group II received an cumulative dose 
mean approximately 15% greater than group I, a statistically 
significant difference (p < 0.001)36,37.
These results partially differ from those found in medical 
literature, since several studies indicated a more evident level 
of myocardial protection granted by dexrazoxane, reason 
why many protocols indicate a greater dose of doxorubicin 
when dexrazoxane is being administered. In a controlled 
study, Wexler et al38 evaluated the effect of dexrazoxane 
in children with soft tissue sarcomas over the period of 
chemotherapy with doxorubicin. Patients were evaluated 
by radionuclide angiography, and the cardiac toxicity was 
defined as an ejection fraction less than 45% or a drop in 
ejection fraction equal to or greater than 20% in relation to 
the pre-chemotherapy value. According to the authors, the 
incidence of myocardial toxicity in the group who received 
dexrazoxane was lower (22% x 67%), although this group had 
received a greater average cumulative dose of doxorubicin 
(410mg/m2 x 310mg/m2). Moreover, the group that received 
the myocardial protective agent showed a longer survival, 
evaluation 1 evaluation 2 evaluation 3 evaluation 4
gI gII gI gII gI gII gI gII
n 37 18 35 16 35 10 33 15
Heart rate (bpm)
M 89 97.4 89.3 91.3 87.6 86.8 91.1 93.1
SD 14.8 19.4 11.6 19.5 14.1 8.5 16.2 12.4
SBP (mmHg)
M 107.7 111.2 107.3 110.6 106.3 109 108.3 110.7
SD 12.6 17.5 11.6 10.6 11.9 11 16.6 15.3
DBP (mmHg)
M 68.8 71.6 68.1 70.6 68.3 67 68.8 68.7
SD 8.1 9.1 7.3 9.9 7.2 8.2 9.2 10.6
GI- group I; GII- group II; n- number of individuals; M- mean; SD- standard deviation; HR- heart rate; DBP- diastolic blood pressure; SBP- systolic blood 
pressure.
Table 5 – Means and standard deviation of heart rate and systolic and diastolic blood pressure in groups I and II in each phase of the study.
evaluation 1 evaluation 2 evaluation 3 evaluation 4
gI gII gI gII gI gII gI gII
n 37 18 35 16 35 10 33 15
Hemoglobin (g/dl)
M 11.82 11.6 9.25 9.54 9.52 10.26 8.12 9.89
DP 1.52 1.98 1.93 1.83 1.31 0.87 1.68 1.45
Creatinine (µmol/l)
M 0.66 0.76 0.6 0.75 0.65 0.8 0.72 0.85
DP 0.17 0.16 0.22 0.17 0.22 0.17 0.24 0.16
GI- group I; GII- group II; n- number of individuals; M- mean; SD- standard deviation. 
 
Table 6 – Means and deviation error of the levels of hemoglobine and creatinine in groups I and II in each phase of the study.
evaluation 2 evaluation 3 evaluation 4
Group I
Mean 174.05 292.38 345.19
S tandard 
error 8.52 21.71 20.3
Group II
Mean 203.79 338.7 405.17
S tandard 
error 10.4 12.48 15.94
 
Table 7 – Means and standard error of the cumulative dose of 
doxorubicin (mg/m2) in each phase of the study.
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in part secondary to the decrease in cardiac events. In a 
controlled study conducted in children with osteosarcoma 
during chemotherapy, Rubio et al22 considered as cardiac 
toxicity a percentage of shortening of the left ventricle equal 
to or smaller than 28%, or a drop in FS% by an absolute 
value equal to or greater than 10 units of the value recorded 
before the beginning of chemotherapy. The authors found a 
considerable decrease of the incidence of subclinical cardiac 
toxicity in the group that received dexrazoxane (14% x 
27%). Schiavetti et al39 analyzed two groups of patients with 
several different types of solid tumors during the period of 
chemotherapy with doxorubicin or a similar drug, associated 
or not with dexrazoxane, and found a smaller incidence of 
cardiac toxicity, defined as a shortening percentage of the 
left ventricle equal to or smaller than 28% in the group that 
received dexrazoxane (zero% x 13.3%). 
evaluation 1 evaluation 2 evaluation 3 evaluation 4
Group I
Mean 37.03 35.67 34.95 35.26
Standard error 3.66 3.84 3.79 3.91
Group II
Mean 36.75 37.21 38.47 38.22
Standard error 3.52 5.64 5.14 4.52
 
Table 8 – Means and standard error of the shortening fraction (%) on echocardiogram in groups I and II in each phase of the study.
group I group II
fS% n % n %
Altered 7 18.9 2 11.1
normal 30 81.1 16 94.4
Total 37 100 18 100
n- number of individuals; FS%- fractional percentage of systolic 
shortening.
 
Table 9 – Occurrence of changes in the left ventricular systolic 
function. 
The fractional percentage of systolic shortening (FS%) is 
recommended as an index to be used for monitoring the 
systolic function of patients already treated or being currently 
treated with anthracyclines, by the Committee of Cardiology 
of the Studies of Children with Cancer in the United States24. 
Indeed, several studies based on the shortening fraction 
and/or the ejection fraction to evaluate the left ventricular 
systolic function showed the applicability of this index36,41,42. 
However, it is known that it has some limitations in evaluating 
the left ventricular systolic function, mainly when the patient is 
undergoing chemotherapy. Undoubtedly, this index is affected 
by some variables that may influence the pre and postload 
of the left ventricle, primarily during chemotherapy, such 
as anemia, fever, volume infusion, and renal failure42. Even 
with histological myocardial changes, when the postload is 
reduced (vasodilatation due to fever), the shortening fraction 
may remain unchanged, and when it is increased (for instance, 
due to hydric overload), these indices may be reduced43. 
According to McKillop et al, the shortening fraction showed 
37% sensitivity and 72% specificity to predict the subsequent 
development of CHF in patients treated with anthracyclines. 
Nevertheless, the authors considered a shortening percentage 
smaller than 25% as abnormal, and this reduced the sensitivity 
and specificity of the method. Had they been used in this 
study, perhaps other echocardiographic parameters of left 
ventricular systolic function, such as the percentage of 
thickening and the systolic stress of the posterior wall, could 
detect a potential difference in the extent of injury of the left 
ventricle between groups I and II, as they are not influenced 
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Fig. 2 – Chart showing the mean of the shortening fraction in groups I and 
II in each phase of the the study.
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Fig. 1 – Chart showing the mean of the cumulative dose of doxorubicin in 
groups I and II in each phase of the study.
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by pre and postload45. Another limitation of this study refers 
to the fact that it did not include any criteria for diastolic 
function evaluation. Since the late 1980s, different studies 
began to consider that the left ventricular diastolic function in 
patients treated with anthracyclines is affected even before the 
systolic function, reason why it became an important aspect 
within this context46-48. New techniques with tissue Doppler 
and the dobutamine stress echocardiogram might also help 
in the cardiac evaluation of patients who are under the risk 
of developing anthracycline-induced cardiac toxicity, since 
they are more sensitive tools for the diagnosis of myocardial 
toxicity49-50.
Other limitations in this study may have influenced the 
results. This was not a randomized study, and the groups 
were formed and treated at different periods. The clinical 
events with occasional signs of heart failure over the course of 
chemotherapy or after the study period were not included in 
the analysis. Another reason is the relatively small number of 
patients participating in both groups. Although the shortening 
fraction is a parameter widely used and with a high level 
of reproducibility and small interobserver variability, it is 
important to emphasize the fact that the echocardiogram 
is a method that relies on the operator who, despite his/her 
experience, may have accidentally influenced the results 
obtained. However, the tests were performed by one single 
observer who did not know in which group or treatment 
phase the patient was.
Due to having occurred during the chemotherapy 
treatment and most of them being transient, the changes in 
the percentage of shortening may be classifed as manifestations 
of acute toxicity. It is worth mentioning that data obtained 
in this study relate to the period of the chemotherapy with 
doxorubicin, and should not be extrapolated to later phases, 
whether mid or long-term, when the seriousness of the left 
ventricular dysfunction is markedly greater. 
Conclusion
Data in this study show that in osteosarcoma patients treated 
with doxorubicin alone or associated with dexrazoxane, the 
left ventricular systolic function, as assessed by the shortening 
fraction mean, had a better performance in the group that 
received dexrazoxane. On the other hand, both groups of 
patients had similar systolic dysfunction.
Supported by: UNIFESP - EPM and CAPES.
Potential Conflict of Interest
No potential conflict of interest relevant to this article 
was reported.
Matos neto et al
lefT VenTRICUlAR SySTOlIC fUnCTIOn ASSeSSed by eChOCARdIOgRAPhy In ChIldRen And AdOleSCenTS 
wITh OSTeOSARCOMA TReATed wITh deXRAzOXAne AlOne OR In COMbInATIOn wITh dOXORUbICIn
References
1. Himelstein BP, Dormans JP. Malignant bone tumors of childhood. 
Pediatr Clin North Am. 1996; 43: 967-84.
2. Hortobagyi GN. Anthracyclines in treatment of cancer: an overviw. Drugs 
1997; 54:1-7.
3. Holland JF, Frei III E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR 
(eds). Cancer medicine. Philadelphia: Lea & Febiger, 1993. p. 2339-45.
4. Gottlieb JA, Lefrak EA, O’Bryan MA. Fatal adriamycin cardioxidation (CMY): 
Prevention by dose limitation. Proc Am Assoc Cancer Res Abstr. 1973; 14: 
88.
5. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline 
cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 
1978; 62: 865-872.
6. Doroshow JH, Locker GY, Baldinger J, Myers CE. The effect of doxorrubicin 
on hepatic and cardiac glutathione. Res Commun Chem Mol Pathol 
Pharmacol. 1979; 26: 285-95.
7. Hasinoff BB. The interation of the cardioprotective agent ICRF-187((+)-1,2-
bis(3,5-dioxopiperazinyl-1-il) propane, its hydrolysis product (ICRF-198) and 
the chelating agents with the Fe (III) and Cu (II) complexes of adriamycin. 
Agents Actions. 1989; 26: 378-85.
8. Green MD, Alderton P, Gross J, Muggia FM, Speyer JL.  Evidence of the 
selective alteration of anthracycline activity due to modulation by ICRF-187 
(ADR-529). Pharmacol Ther. 1990; 48: 61-9.
9. Keizer HG, Pinedo HM, Shuurhuis GJ, Joenje H. Doxorubicin (Adriamycin): 
acritical review of free radical-dependent mechanisms of cytotoxicity. 
Pharmacol Ther. 1990; 47: 219-31.
10. Lefrak EA, Pitha J, Rosenhem S, Gottleib JA. A clinicopathologic analysis of 
adriamycin cardiotoxicity. Cancer. 1973; 32: 302-14.
11. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of 
anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978; 62: 873-9.
12. Von Hoff DD, Layard MW, Basa P, Davis HT Jr, Von Hoff AL, Rozeneweig 
M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann 
Intern Med. 1979; 91: 707-10.
13. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol. 1992; 
19: 529-42.
14. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in 
children and adults. Semin Oncol. 1998; 25 (Suppl. 10): 72-85.
15. Krischer JP, Epstein S, Cuthbertson DD, Gooerin AM, Epstein ML, Lipshultz 
SE. Clinical cardiotoxicity following anthracycline treatment for child hood 
cancer: the pediatric oncology group experience. J Clin Oncol. 1997; 15: 
1544-52.
16. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-
induced cardiotoxicity in children na adults. Crit Rev Oncol Hematol. 1998; 
27:53-68.
17. Shan K, Lincoff A, Yong J. Anthracycline-induced cardiotoxicity. Ann Intern 
Med. 1996; 125: 47-58.
18. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JJC Rey M, Sanger J, 
et al. ICRF-187 permits longer treatment with doxorrubicin in women with 
bresast cancer. J Clin Oncol. 1992; 10:117-27.
19. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. 
Reduction of doxorubicin cardiotoxicity by prolonged continuos infusion. 
Ann Intern Med. 1982; 96: 133-9.
20. Wiseman LR, Spencer CM. Dexrazoxane: a review of its use as a 
cardioprotective agent in patients receiving anthracycline-based 
chemotherapy. Drugs. 1998; 56: 385-403.
21. Bu’Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection 
by ICRF 187 against high dose anthracycline toxicity in children with 
malignant disease. Br Heart J. 1993; 70: 185-8.
22. Rubio M, Wiegman A, Naeff M. ICRF-187 (Cardioxane®) protection against 
doxorubicin induced carciomyopathy in paediatric osteosarcoma patients. 
[Abstract]. Proc Am Soc Clin Oncol. 1995; 14: A440.
23. Steinherz LJ, Graham T, Hurwitz R, Sondheimer NM, Schwartz RG, Shaffer 
EM, et al. Guidelines for cardiac monitoring of children during and after 
anthracycline therapy: report of the Cardiology Committee of the Childrens 
Cancer Study Group. Pediatrics. 1992; 89 (5 Pt 1): 942-9.
705
Original Article
Arq Bras Cardiol 2006; 87(6): 699-706
24. Bielack S, Erttmann T, Winkler K, Landbeck G. Doxorubicin effect of different 
schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989; 
25: 873-82.
25. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of 
doxorubicin by a 6-hour infusion regimen: a prospective randomized 
evaluation. Cancer. 1990; 65: 870-3.
26. Bieling P, Winkler K, Bielack S, et al. Continuos infusion (CI) versus short term 
infusion (SI) of doxorubicin (DOX) in osteosarcoma. Proc Annu Meet Am 
Soc Clin Oncol. 1991.
27. Casper ES, Gaynor JJ, Hajdu SI, Maggil GB, Tan C, Friedrich E, et al. A 
prospective randomized trial of adjuvant chemotherapy with bolus versus 
continuos infusion of doxorubicin in patients with high-grade extremity 
soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991; 68: 
1221-9. 
28. Green MD, Speyer JS, Bottino JC, Blum RH, Wernz JC, Muggia FM. Phase I-II 
study of the continuos infusion of doxorubicin in the treatment of non-small 
cell lung cancer. Cancer Treat Rep. 1984; 68: 681-2.
29. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V. Decreased 
cardiac toxicity of doxorubicin administered by continuos intravenous 
infusion in combination chemotherapy for metastatic breast carcinoma. 
Cancer. 1989; 63:37-45.
30. Chevillard S, Vielh P, Bastian B, Coppey J. A single 24h contact time with 
adriamycin provokes the emergence of reisitant cells expressing the gp 170 
protein. Anticancer Res. 1992; 12: 495-500.
31. Chiron BV. In: Cardioxane Product Monografh. Amsterdan. The Netherlands, 
1995. 
32. Klein HO, Wickramanayake PD, Coerper C, Christian, E, Pohl J, Brock N. 
High-dose ifosphamide and mesna as continuos infusion over five days – A 
phase I/II trial. Cancer Treat Rev. 1983; 10 (Suppl. A): 167-73.
33. Abdul Hamied TA, Parker D, Turk JL. Effects of adriamycin. 4-
hydroperoxycyclophosphamide and Asta Z 7557 (Inn mafosfamide) on the 
release of IL-2 and IL-1 in vitro. Int J Immunopharmacol. 1987; 9:355-61.
34. Lipshultz SE, Colan SD, Gelber RD, Perez-Atheryde AR, Sallan SE, Sanders SP. 
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia 
in childhood. N Engl J Med. 1991; 324: 808-15.
35. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller C. Development 
of a new intensive therapy for acute lymphoblastic leukemia in children at 
increased risk of early relapse. The Memorial Sloan-Kettering. New York – II 
protocol. Cancer. 1993; 72:3120-30.
36. Wexler LH, Berg S, Andrich M, Chen C, Dilaizian VP, DeLaney T, et al. ICRF-
187 reduces doxorubicin-induced cardiotoxicity with no impact on response 
to chemotherapy. Proc Am Soc Clin Oncol. 1993; 29: A1434. 
37. Schiavetti A, Castello MA, Versacci P, Varrasso G, Padula A, Ventriglia F, et al. 
Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: 
preliminary results. Pediatr Hematol Oncol. 1997; 14:213-22.
38. Geidei S, Garn M, Gravinghoff L, Hausdorf G, Morf G, et al. Cardiomyopathy 
after treatment for osteosarcoma: a contribution to cardiotoxicity of 
adriamycin. Klin Paediatr. 1991; 203: 257-61. 
39. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 
4 to 20 years after completing anthracycline therapy. JAMA. 1991; 226: 
1672-877.
40. Hale JP, Lewis IJ. Anthracyclines: cardiotoxicity and its prevention. Arch Dis 
Childhood. 1994; 71: 457-62.
41. Lipshutz SE, Colan SD. The use of echocardiography holter monitoring in the 
assessement of anthracycline-treated patients. In: Brickner JT, Green DM, 
D’Angio GJ. Cardiac toxicity after treatment for childhood cancer. New York: 
Wiley-Liss; 1993. p. 45-62.
42. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. 
Sensitivity and specificity of radionuclide ejection fraction in doxorrubicin 
cardiotoxicity. N Engl J Med. 1983; 106 (5 Pt 1): 1048-56.
43. Sung RY, Huang GY, Shing MK, Oppenheimer SJ, Li CK Lau J, et al. 
Echocardiographic evaluation of cardiac function in paediatric oncology 
patients treated with or without anthracycline. Int J Cardiol. 1997; 60: 
239-48.
44. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, 
et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler 
echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 
1989; 118: 92-8.
45. Schmitt K, Tulzer G, Merl M, Aichhorn G, Grillenberger A, Wiesinger G, 
et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by 
echocardiography: diastolic versus systolic parameters. Eur J Pediatr. 1995; 
154: 201-4.
46. Bu’Lock FA, Mott Mg, Oakhill A, Martin RP. Left ventricular diastolic filling 
patterns associated with progressive anthracycline-induced myocardial 
damage: a prospective estudy. Pediatr Cardiol. 1999; 20: 252-63.
47. Lenk MK, Zeybek C, Okutan V, Ozcan O, Gokeay E. Detection of early 
anthracycline-induced cardiotoxicity in childhood cancer with dobutamine 
stress echocardiography. Turk J Pediatr. 1998; 40; 31: 373-83.
48. Kapusta L, Goot-Loonen J, Thijssen JM, DeGraaf R, Daniels O. Regional 
cardiac wall motion abnormalities during and shortly after anthracyclines 
therapy. Med Pediatr Oncol. 2003; 41: 426-35.
49. Paiva MG, Petrilli AS, Moises VA, Macedo CR, Tanaka C, Campos O. 
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: 
a study using low-dose dobutamine stress echocardiography. Pediatr Blood 
Cancer. 2005; 45: 872-3.
50. Hauser M, Gibson BS, Wilson N. The evaluation of left ventricular function 
in childhood cancer survivors by pharmacological stress echocardiography. 
Neoplasma 2003; 50: 191-7.
Matos neto et al
lefT VenTRICUlAR SySTOlIC fUnCTIOn ASSeSSed by eChOCARdIOgRAPhy In ChIldRen And AdOleSCenTS  
wITh OSTeOSARCOMA TReATed wITh deXRAzOXAne AlOne OR In COMbInATIOn wITh dOXORUbICIn
706
